PARTNER Risk Model (TAVR) Calculator
Patient parameters
Enter pre-procedural clinical variables. Use the units shown for each field.
Clinical context
Risk prediction after transcatheter aortic valve replacement depends on the specific model, its intended population, endpoint, predictor definitions, and validation cohort. A model developed for poor outcome at six months should not be relabelled as a 30-day mortality model.
The PARTNER trial established evidence for TAVR in patients with severe aortic stenosis who were at high surgical risk or considered inoperable. That trial citation alone does not establish the legacy five-variable equation shown in the previous calculator.
Input summary
| Variable | Unit / coding | Validation range |
|---|---|---|
| Age | Years | 18–120 |
| Serum creatinine | mg/dL | 0.1–30 |
| NYHA class III/IV | No = 0; Yes = 1 | 0 or 1 |
| Body mass index | kg/m² | 10–100 |
| Serum albumin | g/dL | 0.1–10 |
References
Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. N Engl J Med. 2010;363:1597–1607.
doi:10.1056/NEJMoa1008232Primary PARTNER trial report; not verified as the source of the legacy five-variable equation.
Predictors of Poor Outcomes After Transcatheter Aortic Valve Replacement: Results from the PARTNER Trial. Circulation. 2015.
Read the open-access publicationThis study evaluates a composite poor outcome, including death or poor quality of life, rather than validating the equation in the legacy file as a 30-day mortality model.
Review of TAVI-specific clinical prediction models and their endpoints.
Read the reviewClinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.